🥇 First rule of investing? Know when to save! Up to 55% off InvestingPro before BLACK FRIDAYCLAIM SALE

Y mAbs Therapeutics (YMAB)

NASDAQ
Currency in USD
15.48
-0.07(-0.45%)
Closed
After Hours
15.09-0.39(-2.52%)

Y mAbs Therapeutics (YMAB) Income Statement & Profits

Advanced Income Statement
Period Ending:
2016
31/12
2017
31/12
2018
31/12
2019
31/12
2020
31/12
2021
31/12
2022
31/12
2023
31/12
Total Revenues
aa.aaaa.aaaa.aaaa.aaaa.aa34.965.2784.82
Total Revenues Growth
aa.aaaa.aaaa.aaaa.aaaa.aa+68.18%+87.03%+29.96%
Cost Of Revenues
aa.aaaa.aaaa.aaaa.aaaa.aa2.517.5711.42
Gross Profit
aa.aaaa.aaaa.aaaa.aaaa.aa32.3857.773.4
Gross Profit Growth
aa.aaaa.aaaa.aaaa.aaaa.aa+74.6%+78.18%+27.21%
Gross Profit Margin %
aa.aaaa.aaaa.aaaa.aaaa.aa92.8%88.41%86.54%
Other Operating Expenses, Total
aa.aaaa.aaaa.aaaa.aaaa.aa147.82141.0294.59
Other Operating Expenses, Total Growth
R&D Expenses
Selling General & Admin Expenses
Other Operating Expenses
Operating Income
aa.aaaa.aaaa.aaaa.aaaa.aa-115.43-83.32-21.19
Operating Income Growth
aa.aaaa.aaaa.aaaa.aaaa.aa+3.75%+27.82%+74.57%
EBIT Margin %
aa.aaaa.aaaa.aaaa.aaaa.aa-330.78%-127.66%-24.98%
Net Interest Expenses
aa.aaaa.aaaa.aaaa.aaaa.aa-1.850.644.81
Net Interest Expenses Growth
aa.aaaa.aaaa.aaaa.aaaa.aa-8,518.18%+134.72%+647.43%
Interest Expense, Total
aa.aaaa.aaaa.aaaa.aaaa.aa-1.85--
Interest And Investment Income
aa.aaaa.aaaa.aaaa.aaaa.aa-0.644.81
Other Non Operating Expenses, Total
aa.aaaa.aaaa.aaaa.aaaa.aa---
EBT, Excl. Unusual Items
aa.aaaa.aaaa.aaaa.aaaa.aa-117.29-82.68-16.38
Gain (Loss) On Sale Of Assets
aa.aaaa.aaaa.aaaa.aaaa.aa62.01--
Other Unusual Items, Total
aa.aaaa.aaaa.aaaa.aaaa.aa--12.89-
EBT, Incl. Unusual Items
aa.aaaa.aaaa.aaaa.aaaa.aa-55.28-95.57-20.87
EBT, Incl. Unusual Items Growth
aa.aaaa.aaaa.aaaa.aaaa.aa+53.68%-72.9%+78.17%
EBT, Incl. Unusual Items Margin
aa.aaaa.aaaa.aaaa.aaaa.aa-158.39%-146.43%-24.6%
Income Tax Expense
aa.aaaa.aaaa.aaaa.aaaa.aa--0.56
Net Income to Company
aa.aaaa.aaaa.aaaa.aaaa.aa-55.28-95.57-21.43
Minority Interest
aa.aaaa.aaaa.aaaa.aaaa.aa---
Net Income
aa.aaaa.aaaa.aaaa.aaaa.aa-55.28-95.57-21.43
Net Income Growth
aa.aaaa.aaaa.aaaa.aaaa.aa+53.68%-72.9%+77.58%
Net Income Margin %
aa.aaaa.aaaa.aaaa.aaaa.aa-158.39%-146.43%-25.26%
Preferred Dividend and Other Adjustments
aa.aaaa.aaaa.aaaa.aaaa.aa---
Net Income to Common Excl. Extra Items
aa.aaaa.aaaa.aaaa.aaaa.aa-55.28-95.57-21.43
Basic EPS - Continuing Operations
aa.aaaa.aaaa.aaaa.aaaa.aa-1.28-2.19-0.49
Basic EPS - Continuing Operations Growth
aa.aaaa.aaaa.aaaa.aaaa.aa+56.97%-70.83%+77.55%
Diluted EPS - Continuing Operations
aa.aaaa.aaaa.aaaa.aaaa.aa-1.28-2.19-0.49
Diluted EPS - Continuing Operations Growth
aa.aaaa.aaaa.aaaa.aaaa.aa+56.97%-70.83%+77.55%
Basic Weighted Average Shares Outstanding
aa.aaaa.aaaa.aaaa.aaaa.aa43.1843.743.65
Diluted Weighted Average Shares Outstanding
aa.aaaa.aaaa.aaaa.aaaa.aa43.1843.743.65
Dividend Per Share
aa.aaaa.aaaa.aaaa.aaaa.aa---
Dividend Per Share Growth
aa.aaaa.aaaa.aaaa.aaaa.aa---
EBITDA
aa.aaaa.aaaa.aaaa.aaaa.aa-114.65-82.48-20.46
EBITDA Growth
aa.aaaa.aaaa.aaaa.aaaa.aa+4.09%+28.06%+75.2%
EBITDA Margin %
aa.aaaa.aaaa.aaaa.aaaa.aa-328.54%-126.37%-24.12%
EBIT
aa.aaaa.aaaa.aaaa.aaaa.aa